1. Nature Japan
  2. Nature Biotechnology
  3. v32 n7
  4. バイオ企業と製薬企業の商品開発のベンチマーキング
Opinion and Comment

バイオ企業と製薬企業の商品開発のベンチマーキング

Nature Biotechnology 32, 7 doi: 10.1038/nbt.2947

The biotech sector's record in originating high-priority medicines exceeds that of the pharmaceutical industry, its costs are lower and its products have comparable revenues.
Full text
PDF

目次へ戻る

advertisement
プライバシーマーク制度